Most of what you've read about we analyzed 10,000 clinical trials: ai predicts drug is wrong. I know because I believed it too, and it cost me.
I've been in the Silicon Valley trenches for over a decade, and I've never seen a shift as massive as AI in healthcare. I'm sharing the hard-won lessons from my own startups and investments—the wins, the failures, and the counterintuitive strategies that actually work.
The Counterintuitive Truth
Here's what surprised me most about we analyzed 10,000 clinical trials: ai predicts drug: the best practitioners do less, not more.
When I was building MovieLaLa, we tried to do everything at once. We had the best technology, the smartest team, and we still almost failed because we spread ourselves too thin.
The lesson I took from that experience, and from watching hundreds of other companies, is that timing is everything in this game. It sounds simple. It's incredibly hard to execute.
The Framework That Actually Works
I'm going to share the exact framework I use when evaluating we analyzed 10,000 clinical trials: ai predicts drug. It's not complicated, but it requires discipline.
Step 1: simplicity beats complexity every time This is where most people go wrong. They skip this step entirely and jump straight to execution. Don't do that.
Step 2: timing is everything in this game Once you have the foundation right, this becomes much easier. I've watched founders struggle with this for months when the answer was staring them in the face.
Step 3: Iterate relentlessly Nothing works perfectly the first time. The companies in my portfolio that nail we analyzed 10,000 clinical trials: ai predicts drug are the ones that treat it as an ongoing process, not a one-time project.
The Reality Nobody Talks About
Most people approach we analyzed 10,000 clinical trials: ai predicts drug with assumptions that made sense five years ago. The world has moved on. When I look at my portfolio companies, the ones that succeed are doing something fundamentally different.
The first thing to understand is that the best solutions are often the simplest ones. I've seen this play out across dozens of companies. The pattern is unmistakable.
At RemoteTeam, we learned this the hard way. We spent months going down the wrong path before realizing that you need to move fast and break things. Once we made the switch, everything changed.
Real Talk: What Actually Matters
I'm going to cut through the noise and tell you what actually matters when it comes to we analyzed 10,000 clinical trials: ai predicts drug.
First, execution speed beats perfection. Every time. I've never seen a company fail because they moved too fast on we analyzed 10,000 clinical trials: ai predicts drug. I've seen plenty fail because they moved too slow.
Second, measure everything. If you can't measure it, you can't improve it. Set up tracking from day one, even if it's basic.
Third, talk to your users. This sounds obvious but you'd be amazed how many founders build their we analyzed 10,000 clinical trials: ai predicts drug strategy in a vacuum. Get out of the building. Talk to real people.
This connects to broader themes around healthcare automation, drug discovery AI, AI diagnostics, AI mental health, medical AI that I've been thinking about a lot lately.
What's Next
The world of we analyzed 10,000 clinical trials: ai predicts drug is moving fast. What worked last year might not work next year. That's both the challenge and the opportunity.
My advice: stay curious, stay humble, and stay close to the people who are actually doing the work. Read less thought leadership and do more experiments. Talk to fewer consultants and more practitioners.
And if you're a founder building in this space, remember that the best time to get we analyzed 10,000 clinical trials: ai predicts drug right is before you need to. Don't wait for a crisis to force your hand.
I'll keep sharing what I learn. This stuff matters too much to keep to myself.
Frequently Asked Questions
What's the most common pushback you get on this?
People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.
How has this view evolved over time?
My thinking on most topics has changed significantly over the years. Early in my career, I held many conventional views that experience proved wrong. I try to update my beliefs when the evidence changes.
What experience informs this perspective?
This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.